Prescription drug · NDA
Pemetrexed (Pemetrexed disodium) NDC 0781-3520
Pemetrexed disodium 1000 mg/40mL · Injection, Solution · Intravenous · Sandoz Inc.
NDC codes
FDA NDC DirectoryProduct information
- Brand name (proprietary)
- Pemetrexed
- Generic name (nonproprietary)
- pemetrexed disodium
- Active ingredients
- Pemetrexed disodium — 1000 mg/40mL
- Dosage form
- Injection, Solution
- Route
- Intravenous
- Labeler
- Sandoz Inc.NDC labeler code 0781
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 214657
- Marketing start
- Listing expires
- Other FDA classes
- Folic Acid Metabolism Inhibitors (Mechanism)
- Identifiers
- Product ID 0781-3520_764ab64b-c642-4314-83a9-efee79fe83a3SPL ID 764ab64b-c642-4314-83a9-efee79fe83a3SPL set ID 7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3RxCUI 2602363, 2602365, 2602366UNII 2PKU919BA9
- Pharmacologic class
- Folate Analog Metabolic Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Pemetrexed Injection is a folate analog metabolic inhibitor indicated: • in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) • in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) • as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) • as a single agent for the treatment of patients wit…
Excerpt only. Read the full label for complete information.
About NDC 0781-3520
- What is NDC 0781-3520?
- 0781-3520 is the product NDC for Pemetrexed (pemetrexed disodium), Pemetrexed disodium 1000 mg/40mL injection, solution, listed with the FDA by Sandoz Inc..
- What drug is associated with this NDC?
- Pemetrexed (Pemetrexed disodium).
- What is the active ingredient?
- Pemetrexed disodium.
- Who is the labeler?
- Sandoz Inc., NDC labeler code 0781. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Pemetrexed?
- 57 other product NDCs are listed under this name. See all Pemetrexed NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Pemetrexed products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Pemetrexedpemetrexed disodium | Pemetrexed disodium heptahydrate 100 mg/4mL | Injection, Powder, Lyophilized, For solutionIntravenous | Somerset Therapeutics LLC | 70069-834 | 70069-0834-01 |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium heptahydrate 500 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | Somerset Therapeutics LLC | 70069-835 | 70069-0835-01 |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 100 mg/4.2mL | Injection, Powder, Lyophilized, For solutionIntravenous | Sagent Pharmaceuticals | 25021-260 | 25021-0260-10 |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 500 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | Sagent Pharmaceuticals | 25021-261 | 25021-0261-50 |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 100 mg/10mL | Injection, Powder, Lyophilized, For solutionIntravenous | NorthStar RxLLC | 72603-325 | 72603-0325-01 |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 500 mg/50mL | Injection, Powder, Lyophilized, For solutionIntravenous | NorthStar RxLLC | 72603-425 | 72603-0425-01 |
| Pemetrexed | Pemetrexed disodium hemipentahydrate 100 mg/1 | Injection, Powder, For solutionIntravenous | Solco Healthcare US, LLC | 43547-632 | 43547-0632-01 |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 100 mg/4mL | Injection, Powder, Lyophilized, For solutionIntravenous | Camber Pharmaceuticals, Inc. | 31722-336 | 31722-0336-31 |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 500 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | Camber Pharmaceuticals, Inc. | 31722-337 | 31722-0337-31 |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 100 mg/10mL | InjectionIntravenous | Shilpa Medicare Limited | 63759-3048 | 63759-3048-01 |
Other NDCs under NDA 214657
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Pemetrexedpemetrexed disodium | Pemetrexed disodium 100 mg/4mL | Injection, SolutionIntravenous | Sandoz Inc. | 0781-3518 |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium 500 mg/20mL | Injection, SolutionIntravenous | Sandoz Inc. | 0781-3519 |